A therapeutic update on the ocular and systemic treatment of diabetes
Date: 12/03/2025 (AEST)
Venue: The Greek Club, 29 Edmondstone Street South Brisbane , QLD, 4101
Provider: LVF Ophthalmology Research Centre
Contact: Christopher Layton, [E] admin@lvfeyecentre.org.au, [P] 07 3398 9494
Activity Outline
This lecture offers a comprehensive look at recent breakthroughs in diabetes management and the evolving landscape of diabetic retinopathy (DR) treatment. It begins by examining the ongoing global challenge of diabetes and the high prevalence of diabetic retinopathy, underscoring the need for up-to-date, evidence-based interventions to prevent vision loss.
Attendees will first explore the latest developments in systemic diabetes therapies, with special attention to novel pharmacological agents such as newly approved or soon-to-be-approved GLP-1 receptor agonists, dual-incretin therapies, and SGLT2 inhibitors. The lecture will address the specific mechanisms of action underlying these innovations, as well as the data supporting their benefits for glycemic control and cardiovascular health. By highlighting the positive effects of improved systemic management on ocular outcomes, the session will illustrate the direct connection between comprehensive diabetes care and the slowing of DR progression.
The discussion then turns to cutting-edge treatments for diabetic retinopathy, including extended-release anti-VEGF injections, investigational agents like faricimab, and the role of corticosteroid implants. In addition, the lecture will review advanced diagnostic tools that allow earlier DR detection and more precise disease monitoring. The utility and limitations of laser therapy, particularly in combination with pharmacological treatments, will also be addressed.
Learning Objectives
- Identify and describe at least two recently approved systemic therapies for diabetes and explain how these innovations impact overall glycemic control and patient outcomes.
- Discuss the latest advances in diabetic retinopathy (DR) management, including emerging pharmacological treatments and cutting-edge imaging techniques, and evaluate their efficacy in reducing vision-threatening complications.
- Develop a structured approach for integrating new diabetic therapies and DR screening methods into optometric practice, with an emphasis on interprofessional collaboration and patient education.
Max CPD hours awarded: 2.5
Session Information
| Name |
|---|
| A therapeutic update on the ocular and systemic treatment of diabetes |
| Clinical? |
| Yes |
| Interactive? |
| Yes |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 2.5 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 2.5 |